Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

(Reuters) -German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they ...

The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

An official overseeing implementation of the Make America Healthy Again agenda at the Department of Health and Human Services ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

WASHINGTON -- So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using ...